Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2023 January Covid-19 Breakthrough COVID-19 in vaccinated patients with haematologic malignancies Read more
2022 November Clinical practice Long-term remission rates after treatment with tisagenlecleucel in paediatric and young adult ... Read more
2022 September Editor's pick Relevant literature for your daily clinical practice selected by: André Bosly Read more
2022 May Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: JAN PHILIPPÉ Read more
Top
